Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

This study tests a procedure called hepatic melphalan delivery — where a high dose of chemotherapy is delivered directly into the liver's blood supply — in combination with standard approved cancer treatments for people with metastatic colorectal cancer that has spread mainly to the liver. **You may be eligible if...** - You have been diagnosed with metastatic colorectal cancer confirmed by biopsy - The majority of your cancer burden is in the liver, and the liver tumors cannot be surgically removed or ablated - Your liver tumors take up 50% or less of the liver volume - Any cancer outside the liver is limited, and the liver disease is the most life-threatening component - Your liver lesions are measurable on CT or MRI **You may NOT be eligible if...** - Cancer outside the liver is extensive or life-threatening in its own right - Your liver lesions occupy more than 50% of the liver - You have significant health conditions that would make the procedure unsafe Talk to your doctor to see if this trial is right for you.